Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FL-501
- Development stage
- Discontinued
- Lead developer
- Leap Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
FL-501 is a fully human, monoclonal antibody engineered to neutralize growth differentiation factor 15 (GDF-15), a cytokine implicated in cancer cachexia and a range of GDF-15-related diseases. It prevents GDF-15 from binding its receptor, resulting in reversal of immunosuppression in certain cancers and improvement of weight loss and muscle mass. FL-501 features enhanced target affinity and an extended plasma half-life compared to prior antibodies. Preclinical models demonstrate full restoration of body composition in cachexia, superior pharmacokinetics, and potential efficacy in immune stimulation and organ protection. Developed and currently being advanced by Leap Therapeutics, initially originated by Flame Biosciences and Adimab, FL-501 is planned for clinical trials in cachexia and other GDF-15-linked conditions including certain cancers[1][2][3][4][5][6][7][9].
- Other names
- FL-501FL501FL 501
02
Targets
GDF15 (Growth differentiation factor 15)
Beyond the preview
Go deeper on FL-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FL-501.